Pneumonitis Prediction App


Pneumonitis Prediction App

Tool for estimating risk of Grade 2 and Grade 3 Pneumonitis in lung cancer patients.

Disclaimer

The software designer and provider, including any collaborating institution(s), including the University of Michigan, shall have no liability to any patient or any other person. No such person or entity assumes any legal liability or responsibility for the accuracy, completeness, suitability, or usefulness of the 'Pneumonitis Predicition App' or related any information. Any and all liability arising directly or indirectly from the use of this application is hereby disclaimed. The information herein is provided 'as is' and without any warranty expressed or implied, including the warranties of merchantability and fitness for a particular purpose.

Predicting Grade 2+ Pneumonitis

Model Inputs:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):
Probability of pneumonitis:
The listed probabilities refer to the probability of developing G2+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.

Predicting Grade 3+ Pneumonitis

Model Inputs:

Comorbidities included in count: Hypertension; Diabetes mellitus; Scleroderma; Rheumatoid arthritis; Lupus; Cerebrovascular disease; Chronic pulmonary disease; Congestive heart failure; Connective tissue damage; Confusion; Hemiplegia; Leukemia; Malignant lymphoma; Myocardial infarction; Peripheral vascular disease; Liver disease; Renal disease; Malignant solid tumor (other than lung)
Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):
Probability of pneumonitis:
The listed probabilities refer to the probability of developing G3+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.

Predicting Grade 2+ and 3+ Pneumonitis

Model Inputs:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):
Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):
Comorbidities included in count: Hypertension; Diabetes mellitus; Scleroderma; Rheumatoid arthritis; Lupus; Cerebrovascular disease; Chronic pulmonary disease; Congestive heart failure; Connective tissue damage; Confusion; Hemiplegia; Leukemia; Malignant lymphoma; Myocardial infarction; Peripheral vascular disease; Liver disease; Renal disease; Malignant solid tumor (other than lung)
The listed probabilities refer to the probability of developing G2+ or G3+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.

Comparing Plans

Patient Information:

Plan #1:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):
Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):

Plan #2:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):
Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):
Comorbidities included in count: Hypertension; Diabetes mellitus; Scleroderma; Rheumatoid arthritis; Lupus; Cerebrovascular disease; Chronic pulmonary disease; Congestive heart failure; Connective tissue damage; Confusion; Hemiplegia; Leukemia; Malignant lymphoma; Myocardial infarction; Peripheral vascular disease; Liver disease; Renal disease; Malignant solid tumor (other than lung)
The listed probabilities refer to the probability of developing G2+ or G3+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.

Patient Information:

Plan #1:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):

Plan #2:
Predicted Probability of Pneumonitis Grade 2+ (95% Prediction Interval):
Comorbidities included in count: Hypertension; Diabetes mellitus; Scleroderma; Rheumatoid arthritis; Lupus; Cerebrovascular disease; Chronic pulmonary disease; Congestive heart failure; Connective tissue damage; Confusion; Hemiplegia; Leukemia; Malignant lymphoma; Myocardial infarction; Peripheral vascular disease; Liver disease; Renal disease; Malignant solid tumor (other than lung)
The listed probabilities refer to the probability of developing G2+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.

Patient Information:

Plan #1:

Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):

Plan #2:

Predicted Probability of Pneumonitis Grade 3+ (95% Prediction Interval):
Comorbidities included in count: Hypertension; Diabetes mellitus; Scleroderma; Rheumatoid arthritis; Lupus; Cerebrovascular disease; Chronic pulmonary disease; Congestive heart failure; Connective tissue damage; Confusion; Hemiplegia; Leukemia; Malignant lymphoma; Myocardial infarction; Peripheral vascular disease; Liver disease; Renal disease; Malignant solid tumor (other than lung)
The listed probabilities refer to the probability of developing G3+ pneumonitis within 6 months after the conclusion of treatment with radiation, in patients not treated with immunotherapy.